✓
Open
29 Aug 2017
✓
Close
31 Aug 2017
3
Allotment
—
✓
Listing
Fri, Sep 8, 2017
Price Band
₹80 per share
Issue Size
15,00,800 shares (agg. up to ₹12 Cr)
Lot Size
1,600 Shares
Listing Date
Fri, Sep 8, 2017
✦ AI Insight
Live Subscription
| Category | Subscription (times) |
|---|---|
| Total | 8.07x |
Restated Financials (₹ Cr.)
| Period Ended | 31 Mar 2017 | 31 Mar 2016 | 31 Mar 2015 |
|---|---|---|---|
| Assets | 46.86 | 35.49 | 25.84 |
| Total Income | 67.92 | 55.13 | 36.94 |
| Profit After Tax | 2.92 | 1.65 | 0.40 |
| NET Worth | 7.59 | 4.77 | 3.12 |
| Reserves and Surplus | 3.91 | 1.09 | -0.57 |
| Total Borrowing | 11.58 | 11.77 | 10.14 |
| Amount in ₹ Crore |
Peer Comparison
| Company | Issue Type | Issue Size | Issue Price | PE Ratio | Listing Day Close | Listing Gain/Loss % | LTP |
|---|---|---|---|---|---|---|---|
| Vaishali Pharma Ltd. | SME | ₹14.23 Cr | ₹72 | null | ₹70.35 | -2.29% | ₹7.87 (+0.51%) |
| Zota Health Care Ltd. | SME | ₹58.50 Cr | ₹125 | null | ₹125.60 | +0.48% | ₹1,277.40 (-4.03%) |
| Sakar Healthcare Ltd. | SME | ₹14.81 Cr | ₹50 | null | ₹52.15 | +4.30% | ₹837.25 (-4.72%) |
| Eris Lifesciences Ltd. | Mainboard | ₹1,740.49 Cr | ₹603 | null | ₹601.50 | -0.25% | ₹1,440.60 (-1.95%) |
| Laurus Labs Ltd. | Mainboard | ₹1,330.51 Cr | ₹428 | null | ₹480.40 | +12.24% | ₹1,577.80 (-0.96%) |
Objects of the Issue
| # | Issue Objects | Est Amt (₹ Cr.) |
|---|---|---|
| 1 | To meet the working capital requirement | 11.64 |
| 2 | To meet the Issue Expenses | 0.37 |
About ANG Lifesciences IPO
Incorporated in 2006, ANG Lifesciences India Limited is a pharmaceutical company whose engaged in the business of manufactures and markets finished pharmaceutical formulations in a dosage form of sterile dry powder injection vials in India.Company's products include sterile dry powder vials for anti-biotics, anti-ulcerant, glucocorticoid and anti-inflammatory, anti-malarial, and anesthetic. It manufactures products in compliance with GMP requirements.However, Company that currently operates at an average capacity utilization of 70% for last two fiscals hopes to achieve 90% plus in coming years. ANGL is likely to consider acquisition options as well to enhance its manufacturing capacities. Its customer list includes Wockhardt, DHS Maharashtra, Global Hospitals, Elder, Emcure, BPPI, Govt. of Haryana, Hetero Healthcare etc.+ Read More
Contact Details
ANG Lifesciences India Ltd. AddressDarbara Complex SCO 113 I FlrDist.Shopping Centre B BlockAmritsar, Punjab, 143001+91-0183-5070118cs@anglifesciences.comVisit Website